Blue test tubes arranged in a line, disappearing into the background

Drug news

Paclical (paclitaxel water-soluble formulation) approved in Russia for Ovarian Cancer-Oasmia Pharma

Read time: 1 mins

Last updated: 21st Apr 2015

Published: 21st Apr 2015

Source: Pharmawand

Oasmia Pharmaceutical AB announced that its lead cancer product Paclical (paclitaxel water-soluble formulation) received market authorization in the Russian Federation by the Russian Ministry of Health. Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization. Paclical is planned for launch in the second half of 2015. Paclical is a novel formulation of paclitaxel based on Oasmia's XR-17 technology, which is non-toxic and forms water soluble nanoparticles with paclitaxel.

Doctor holding patients hand in consultation

Learning Zone

Supportive Care in Oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Learning Zone

PARP Inhibitor Selection in Ovarian Cancer Learning Zone

Up to date on the latest treatments for advanced ovarian cancer? Get expert insights and case studies on PARP inhibitors in ovarian cancer.

How do you prefer to access medical updates and information?

Listen to a podcast

Watch a video

Read an article

Other

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Moderna reports H5 Flu data

Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.

Drug news

Cibotercept in PAH ends

Published: 30th May 2025

Drug news

Khindivi cleared for pediatrics

Published: 30th May 2025

See all news